Kenyans living with HIV/AIDS have been urged to take their antiretroviral (ARV) medication daily without fear of shortages.
The Division of National AIDS and STI Control Program has confirmed that there is sufficient stock of ARVs for both prevention and treatment at all Antiretroviral Therapy (ART) sites. Patients are advised not to skip doses, share medication, or refill prescriptions before their due dates.
This reassurance comes amidst concerns over potential disruptions following the suspension of USAID funding, which previously supported Kenya’s HIV/AIDS treatment efforts through the PEPFAR program. The U.S. government has invested over $8 billion in HIV treatment in Kenya over two decades, covering nearly 1.3 million people.
Despite reports of dwindling stocks of Dolutegravir and Nevirapine, key HIV treatment drugs, Health CS Deborah Barasa assured that supplies will last for several months once replenished by the Mission for Essential Drugs and Supplies (MEDS).
Director-General for Health Patrick Amoth also reaffirmed that the government has strengthened supply chains to ensure the continuous availability of ARVs, assuring Kenyans that HIV treatment will remain uninterrupted.
